Acute Optic Neuritis, Multiple Sclerosis
Conditions
Keywords
Healthy Volunteer, opicinumab
Brief summary
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers. Secondary objectives are: To assess the safety and tolerability of BIIB033-A and BIIB033-B; To assess the secondary PK parameters of BIIB033-A and BIIB033-B; To assess the immunogenicity of BIIB033-A and BIIB033-B.
Interventions
Sponsors
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * \- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations. * \- Must have a body mass index of 18 to 32 kg/m2, inclusive. * \- All male participants and all female participants of childbearing potential must practice highly effective methods of contraception during the study and be willing and able to continue contraception for 6 months after being dosed with study treatment. Male participants must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study. Male participants must also be willing to refrain from sperm donation for at least 6 months after dosing with study treatment. * \- Must be in good health as determined by the Investigator (or designee), based on medical history and screening evaluations. Key
Exclusion criteria
* \- History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or other major disease, as determined by the Investigator. * \- History of or ongoing malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to Day -1). * \- Serious infection (e.g., pneumonia, septicemia) as determined by the Investigator, within the 3 months prior to Day -1. * \- Fever or bacterial or viral infection (including upper respiratory tract infection) within 2 weeks prior to Day -1. * \- History of severe allergic or anaphylactic reactions, or history of any allergic reaction that in the opinion of the Investigator is likely to be exacerbated by any component of the study treatment. * \- Prior exposure to BIIB033. * \- Female participants who are breastfeeding or pregnant at Screening or Day -1, or plan to become pregnant during the study or during the 6 months following study drug administration. * \- History of, or positive test result at Screening for, human immunodeficiency virus. * \- History of, or positive test result at Screening for, hepatitis C virus antibody or hepatitis B virus (defined as positive for hepatitis B surface antigen or hepatitis B core antibody). NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK parameter of BIIB033: Area under the concentration-time curve from time 0 to infinity (AUC0-inf) | Up to Day 89 |
| PK parameter of BIIB033: Area under the concentration-time curve from time 0 to Day 85 (AUC84d) | Day 85 |
| PK parameter of BIIB033: Maximum observed concentration (Cmax) | Up to Day 89 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with clinically significant electrocardiograms (ECGs) abnormalities | Up to 17 weeks |
| Number of participants with clinically significant physical examination abnormalities | Up to 17 weeks |
| PK parameter of BIIB033: Time to reach maximum observed concentration (Tmax) | Up to Day 89 |
| Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 17 weeks |
| PK parameter of BIIB033: Volume of distribution at steady state (Vss) | Up to Day 89 |
| PK parameter of BIIB033: Clearance (CL) | Up to Day 89 |
| Number of participants with presence of anti-BIIB033 antibodies | Pre-dose, Day 22 and Day 85 |
| PK parameter of BIIB033: Terminal elimination half-life (t1/2) | Up to Day 89 |
| Number of participants with clinically significant laboratory parameters | Up to 17 weeks |
| Number of participants with clinically significant vital sign abnormalities | Up to 17 weeks |
Countries
United States
Outcome results
None listed